Cureous Labs, a medical technology company, based in Bengaluru raised ₹1.66 crore in seed funding. The seed round was led by Inflection Point Ventures (IPV) and had participation by Anthill Ventures.The company intends to use the funding to speed up the commercial rollout of its flagship product Eturnal, and could also use it to expand its presence in India, a growing healthcare market.

Funding to Power Expansion and Certification

The new capital will be strategically deployed across multiple operational areas. Cureous Labs plans to use the funds to:

• Manufacture the first commercial batch of Eturnal™ devices
• Build and maintain inventory to meet growing demand
• Expand the sales and business development teams for deeper market penetration
• Establish its first dedicated disinfection centre for safe handling and maintenance
• Complete rigorous product safety testing and obtain essential certifications
• Broaden its B2B product portfolio for institutional clients across India

These moves will help the startup shift from pilot programs to full-scale commercial deployment, positioning it to serve both institutional and home-care segments effectively.

Eturnal™: Affordable Automation for Better Patient Care

Cureous Labs was founded by Asish Mohandas. It focuses on innovative medical solutions that include technology, affordability and practicality. Eturnal™, is India’s first retrofit automated patient-repositioning system. Designed to prevent pressure injuries, commonly known as bedsores the device automatically repositions patients at regular intervals, reducing both patient discomfort and the physical burden on caregivers.

What sets Eturnal™ apart is its cost advantage. Priced at just one-fifth of comparable international systems, it offers hospitals, rehabilitation centres, and home caregivers a high-quality, budget-friendly alternative. The device has undergone more than two years of clinical research in over 100 hospitals across India and Australia. It has already logged 30,000+ operational hours and successfully carried out 14,000+ automated patient turns in live healthcare settings.

Currently, Cureous Labs is running active B2B and B2C pilots in South India to fine-tune deployment strategies and gather market insights.

Also Read: Anecdote: Sagar Azad’s Hybrid Publishing Journey

Founder’s Expertise in Healthcare Innovation

Asish Mohandas brings deep expertise in biomedical design and innovation. A Biodesign Fellow from AIIMS and IIT Delhi, he previously won the India James Dyson Award for a patient-care device he developed at IIT Kanpur. His mission with Cureous Labs is to make advanced patient-care technologies accessible to all, especially in resource-limited healthcare settings.

Strong Backing from Preventive Healthcare Advocates

For investors like IPV, the attraction was in the prevention aspect of the company, not the treatment aspect. Vinay Bansal, Founder of Inflection Point Ventures, remarked that Cureous Labs addresses two gap areas, decreases the prevalence of pressure injuries in bedridden patients, and decreases the pressure on caregivers. He has pointed out that solutions like these can change patient outcomes, while reducing costs for the healthcare providers.

Global and Domestic Market Potential

The addressable market for Cureous Labs’ solution is enormous. There are around 154 million bedridden people worldwide, who are at risk of pressure injuries, and the market for elderly care and patient care is valued at USD277 billion. In India, the statistics are compelling:

• Total Addressable Market (TAM) of USD 8.34 billion
• Serviceable Available Market (SAM) of USD 1.56 billion
• Serviceable Obtainable Market (SOM) of USD 656 million

These figures reflect the rising demand for affordable, effective long-term care solutions, especially as India’s elderly population grows and more families turn to home-based care.

Recognition from Leading Global Institutions

Cureous Labs has earned recognition from several prestigious bodies for its innovative work in healthcare technology. The company has been supported by:

• BIRAC (Biotechnology Industry Research Assistance Council)
• MeitY (Ministry of Electronics & Information Technology)
• Bill & Melinda Gates Foundation
• Swissnex AIT
• Social Alpha
• SBI Foundation

Such endorsements not only validate the technology but also underscore its potential to create a measurable social impact.

Vision for the Future

Looking ahead, Cureous Labs aims to scale up manufacturing, expand nationwide, and introduce complementary products to strengthen its portfolio. Mohandas shared, “At Cureous, our mission is to empower independent living. Eturnal™ not only helps prevent pressure injuries but also significantly reduces caregiver dependency and effort. With IPV’s belief in our vision, we are confident about becoming a category-defining force in geriatric and long-term care.”

Conclusion

This ₹1.66 crore seed funding round is a significant point of inflection for Cureous Labs. With the product working, investors onboard, and experts from prestigious organisations backings us (UK CCG), Cureous Labs is finally in a great spot to tackle one of the most pressing problems in patient care. Cureous Labs will be using affordability, automation, and clinical dependability, to create a change across hospitals, rehabilitation centres, and households in supporting the prevention of pressure injuries, improving the quality of life of patients, while reducing some of the burden on those caring for them.

Also Read: Conscious Chemist: Crafting an “Active-First” Skincare Powerhouse